Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bridgepoint Growth in conjunction with the entry of a partnership in DCHud Holding AB
Mandate

Vinge advises Bridgepoint Growth in conjunction with the entry of a partnership in DCHud Holding AB

November 10, 2020 Employment and Benefits Commercial Agreements M&A Corporate Crime & Compliance

Diagnostiskt Centrum Hud, the leading provider of medical dermatology services in Sweden, partnered with Bridgepoint Growth to further support the company’s expansion.

Today DCH operates six clinics across four Swedish cities and is the clear market leader in Sweden.

Vinge’s team primarily consisted of partner Daniel Rosvall together with associates Michaela Cronemyr, Elsie Nassar, Ellinor Wargenbrant and Olivia Belding (M&A) and Sara Strandberg (employment), Lisa Hörnqvist (commercial agreements) and Tove Lövgren Frisk (corporate, crime & compliance).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025